Gene Therapy Restores Hearing in Individuals with Autosomal Recessive Deafness 9
Researchers have made a significant breakthrough in the field of genetic medicine by developing a gene therapy that can restore hearing in individuals with autosomal recessive deafness 9, a form of congenital hearing loss caused by OTOF gene mutations. The study, published in Nature Medicine, evaluated ten patients ranging from toddlers to young adults and found that a single injection of AAV-OTOF gene therapy delivered via the Anc80L65 capsid into the inner ear resulted in a marked improvement in auditory function within just one month of treatment.
Key Takeaways:
- The average pure-tone hearing threshold improved from 106 to 52 decibels in all ten participants, a dramatic difference for individuals born with profound hearing loss.
- The effect was most pronounced in children aged 5 to 8 years, who demonstrated the most consistent gains, but patients across all age ranges experienced benefit.
- The treatment was well tolerated, with no serious side effects reported over the course of 6 to 12 months of follow-up.
- The most common mild reaction was a temporary drop in neutrophil count, a type of white blood cell.
- The study suggests that the ear's ability to recover is closely tied to age, with children under the age of 8 responding best to the treatment.
Statistics:
- The average pure-tone hearing threshold improved from 106 to 52 decibels, a 58% improvement.
- 100% of participants experienced better hearing after receiving the treatment.
- The treatment was most effective in children aged 5 to 8 years, with an average improvement of 70 decibels.
- The study had a follow-up period of 6 to 12 months, during which no serious adverse events were reported.
- The treatment was delivered via the round window of the cochlea, a non-invasive method.
Sources:
- AAV gene therapy for autosomal recessive deafness 9: a single-arm trial - Nature Medicine
- Source-Medindia Published by HT Digital Content Services with permission from Medindia.